Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Net Cash Flow (2020 - 2025)

Vivos Therapeutics (VVOS) has disclosed Net Cash Flow for 6 consecutive years, with -$1.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Cash Flow fell 130.41% to -$1.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$14.7 million, a 374.31% decrease, with the full-year FY2024 number at $4.6 million, up 352.3% from a year prior.
  • Net Cash Flow was -$1.4 million for Q3 2025 at Vivos Therapeutics, up from -$9.4 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $20.1 million in Q2 2021 to a low of -$9.4 million in Q2 2025.
  • A 5-year average of -$1.4 million and a median of -$3.1 million in 2023 define the central range for Net Cash Flow.
  • Biggest YoY gain for Net Cash Flow was 6461.17% in 2021; the steepest drop was 1054.72% in 2021.
  • Vivos Therapeutics' Net Cash Flow stood at -$4.5 million in 2021, then increased by 28.66% to -$3.2 million in 2022, then surged by 121.88% to $703000.0 in 2023, then crashed by 107.25% to -$51000.0 in 2024, then plummeted by 2574.51% to -$1.4 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Net Cash Flow are -$1.4 million (Q3 2025), -$9.4 million (Q2 2025), and -$3.9 million (Q1 2025).